Treatment of HIV-related non-Hodgkin's lymphoma (NHL) with chemotherapy (CT) and G-CSF: reduction in the days of hospitalization and toxicity with concomitant overall reduction in the cost (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Proc Annu Meet Am Soc Clin Oncol; 12:A13 1993. Unique Identifier : AIDSLINE ICDB/93694413
Tirelli U; Errante D; Vaccher E; Tavio M; Accurso V; Bernardi D; Talamini R; Spina M; Div. of Medical Oncology and AIDS Program, Italy

Abstract: Treatment of HIV-related NHL with CT is associated with an increased risk of side effects, in particular bone marrow toxicity. The aim of this study is to compare the toxicity and the cost of CT with G-CSF vs CT without G-CSF. We have analyzed 37 consecutive patients (pts) treated with intensive CT regimens, 19 pts from July 1989 to June 1991 without G-CSF and 18 pts from July 1991 to September 1992 with G-CSF, 5 ug sc/day starting 24 hr after CT for 13 days in all cycles. The CT regimens employed were the LNH 84 regimen (Coiffier et al, JCO 8:1018-26, 1989) composed by Adriamycin, cyclophosphamide, vindesine, bleomycin, and prednisone and the CHOP-like regimen, CHVmP/VCR-BLM (Carde et al, Ann Oncol 2:431-6, 1991) given for 3-6 cycles. The analysis was performed only for the first 3 cycles of CT. The cost of 1 day of hospitalization in our division is about 450 US dollars. Patient characteristics and results of the study are summarized in a table. The side effects of G-CSF were uncommon and mild. We have shown that treatment with G-CSF significantly reduced the nadir WBC in pts with CD4+ greater than or equal to 200, the mean delay between the CT cycles and the mean toxicity related days of hospitalization. Therefore, by contrast with what one might expect, the cost of CT+G-CSF vs CT alone did not increase, actually it decreased. In addition, a decreased incidence of mucositis was observed, while there is not yet a positive impact on the overall response rate. In conclusion, G-CSF in addition to CT should be preferred in the treatment of pts with HIV-related NHL.

Keywords: Adolescence Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Combined Modality Therapy Cost Control Female Granulocyte Colony-Stimulating Factor/*ADMINISTRATION & DOSAGE Hospitalization/*ECONOMICS Human Lymphoma, AIDS-Related/*DRUG THERAPY/ECONOMICS Male Middle Age ABSTRACT
931230
M93C0804

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .